Skip to content
The Morning Dispatch: Is Vaccine Tech Too Precious to Patent?

The Morning Dispatch: Is Vaccine Tech Too Precious to Patent?

Plus: Ongoing unrest in Burma, and a look at Liz Cheney's likely successor in House leadership.
The Dispatch Staff /
The Morning Dispatch: Is Vaccine Tech Too Precious to Patent?

Happy Friday! We hope we are not the first to remind you that Mother’s Day is this Sunday. Order those flowers! Mail that card! Make those brunch reservations! Buy that gift membership to The Dispatch! 

Quick Hits: Today’s Top Stories

  • Florida Gov. Ron DeSantis signed into law on Thursday a package of election reforms passed by the state legislature last week with only Republican support. The bill, S.B. 90, will require Floridians to reapply for absentee ballots every year and limits ballot drop boxes to election supervisors’ offices or early-voting sites, among other provisions.

  • South Carolina Gov. Henry McMaster on Thursday ordered the state’s Department of Employment and Workforce to cease participation in federal and pandemic-related unemployment benefit programs, effective June 30. McMaster said employers in the state face an “unprecedented labor shortage,” which he attributed in large part to the $300-per-week federal unemployment insurance boost.

  • Initial jobless claims decreased by 92,000 week-over-week to 498,000 last week, the Labor Department reported on Thursday, the lowest level since March 14, 2020.

  • The United States confirmed 46,644 new cases of COVID-19 yesterday per the Johns Hopkins University COVID-19 Dashboard, with 3.0 percent of the 1,566,493 tests reported coming back positive. An additional 789 deaths were attributed to the virus on Thursday, bringing the pandemic’s American death toll to 580,054. According to the Centers for Disease Control, 33,808 Americans are currently hospitalized with COVID-19. Meanwhile, 2,406,932 COVID-19 vaccine doses were administered yesterday, with 149,462,265 Americans having now received at least one dose.

A Worldwide Fight Over COVID IP

As COVID cases fester around the world, particularly hard-hit nations desperate for more vaccines have spent recent months lobbying the World Trade Organization (WTO) with a remarkable argument: COVID vaccines and treatments are too important to remain in the hands of a few private companies.

Want to see more of The Dispatch in Google search?

Add Us as a Preferred Source

Newsletter selected

Click sign up to start receiving your newsletters.

More We Think You’d Like

Newsletter selected

Click sign up to start receiving your newsletters.

Loading